Literature DB >> 12800413

[An investigation on clinical studies of TCM in preventing and treating angina pectoris of coronary heart disease].

Yu-tao Fang1, Shuo-ren Wang.   

Abstract

OBJECTIVE: To analyze the current status of clinical studies of TCM in preventing and treating angina pectoris of coronary heart disease.
METHODS: A statistical analysis of articles regarding the use of TCM in preventing and treating angina pectoris, published in TCM core journals or journals of TCM university (college) from January 2001 to June 2002 was conducted, the items analyzed included the differentiation of stable angina (SA) and unstable angina (UA), the grading or stratifying, standard for therapeutic efficacy evaluation, standardized drug therapy of UA (according to the "Suggestion on the diagnosis and treatment of UA" formulated by Society of Cardiovascular Disease, Chinese Medical Association, etc.
RESULTS: From the 44 articles that retrieved, UA and SA was not differed in 29 articles (65.9%), among which 11 articles came from provincial, national TCM institute or hospital affiliated to TCM university (college). In the 34 articles dealing with UA, only 3 articles mentioned the standardized drug therapy. Standard of therapeutic efficacy evaluation announced in 1979 was used in 35 articles (79.5%).
CONCLUSION: Most articles dealing with clinical study on TCM prevention and treatment of angina pectoris, UA and SA, have the flaws of un-standardized, lacking in compact and insufficient science. Improvement of related standard for clinical therapeutic efficacy evaluation needs to be further perfected.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12800413

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  1 in total

Review 1.  Applications of data mining methods in the integrative medical studies of coronary heart disease: progress and prospect.

Authors:  Yan Feng; Yixin Wang; Fang Guo; Hao Xu
Journal:  Evid Based Complement Alternat Med       Date:  2014-12-03       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.